20.500.12556/RUL-136448 Serum calretinin as a biomarker in malignant mesothelioma The early diagnosis of malignant mesothelioma (MM) could improve the prognosis of MM patients. To confirm an MM diagnosis, an immunohistochemical analysis of several tumor tissue markers, including calretinin, is currently required. Our aim is to evaluate serum calretinin as a potential biomarker in asbestos-related diseases, especially in MM. Our study includes 549 subjects: 164 MM patients, 117 subjects with asbestosis, 195 subjects with pleural plaques and 73 occupationally asbestos-exposed subjects without asbestos-related diseases. The serum calretinin concentration was determined with a commercially available enzyme immunoassay. Data on the soluble mesothelinrelated peptides (SMRP) concentration are available from previous studies. MM patients had a significantly higher calretinin concentration than subjects without disease, subjects with pleural plaques or subjects with asbestosis (all p < 0.001). The histological type was significantly associated with serum calretinin: patients with sarcomatoid MM had lower calretinin than patients with the epithelioid type (p = 0.001). In a ROC curve analysis, the area under the curve for calretinin concentration predicting MM was 0.826 (95% CI = 0.782–0.869; p < 0.001). At the cutoff value of 0.32 ng/mL, sensitivity was 0.683, while specificity was 0.886. The combination of calretinin and SMRP had the highest predictive value. Calretinin is a useful biomarker that can distinguish MM from other asbestos-related diseases and could, therefore, contribute to an earlier non-invasive diagnosis of MM. malignant mesothelioma calretinin asbestos-related disease biomarker maligni mezoteliom kalretinin bolezen povezana z azbestom true false true Angleški jezik Slovenski jezik Članek v reviji 2022-05-04 14:40:55 2022-05-04 14:40:57 2022-09-15 04:13:53 0000-00-00 00:00:00 2021 0 0 11 str. iss. 21, art. 4875 Vol. 10 2021 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-057 2077-0383 10.3390/jcm10214875 83032579 jcm-10-04875-v2.pdf jcm-10-04875-v2.pdf 1 8D85F23F783592C588B88965A15C467C e52a7d7a72ad26e52aeaab4934224256fc7a4cd8d6ab90e3ed56adf5a581c7f2 91eeb8be-cba7-11ec-8aca-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=156110 https://www.mdpi.com/2077-0383/10/21/4875 1 5aa291c5-cba7-11ec-8aca-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=156108 Medicinska fakulteta 0 0 0